Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
An update from Ascentage Pharma Group International ( (HK:6855) ) is now available.
Ascentage Pharma reported a 90% year-on-year increase in 2025 product sales and commercial rights revenue to RMB574.1 million, driven by strong growth of its leukemia drug Olverembatinib and the launch of Lisaftoclax in China. The company also strengthened its balance sheet with a NASDAQ IPO and a follow-on share placement in Hong Kong, becoming the first biopharma to achieve a dual listing on NASDAQ after an HKEX listing.
Commercialization advanced as Olverembatinib completed its first full year under China’s national reimbursement list, while Lisaftoclax won Chinese approval for previously treated CLL/SLL patients and was rapidly launched. On the R&D front, Ascentage secured FDA and EMA clearance for global Phase III trials of Lisaftoclax in higher-risk myelodysplastic syndrome and Olverembatinib in first-line Ph+ ALL, contributing to a total of nine ongoing registrational studies.
These milestones underscore Ascentage Pharma’s push to position itself as a global leader in innovative hematology-oncology therapies. The combination of accelerating commercial momentum in China, an expanding late-stage pipeline, and enhanced access to international capital markets is expected to support further global expansion and long-term value creation for stakeholders.
The most recent analyst rating on (HK:6855) stock is a Hold with a HK$46.00 price target. To see the full list of analyst forecasts on Ascentage Pharma Group International stock, see the HK:6855 Stock Forecast page.
More about Ascentage Pharma Group International
Ascentage Pharma Group International is a global, commercial-stage biopharmaceutical company focused on discovering, developing and commercializing novel, differentiated therapies for cancers with high unmet medical need. The company concentrates on hematology-oncology, advancing small-molecule drug candidates and expanding its presence from Hong Kong to major global markets, including a dual listing on NASDAQ.
Average Trading Volume: 2,031,306
Technical Sentiment Signal: Sell
Current Market Cap: HK$15.58B
For an in-depth examination of 6855 stock, go to TipRanks’ Overview page.